Home›Trial›NCT06295692
🔬NCT06295692Phase 3ACTIVE NOT RECRUITING

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Study Summary

The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).

Conditions
Generalized Pustular PsoriasisErythrodermic Psoriasis
Interventions / Drugs
JNJ-77242113
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment19 participants
Primary Completion—
Lead SponsorJanssen Pharmaceutical K.K.
Data Retrieved2026-04-11 02:55:31.550026+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.